If Visionix’s OCT products are fourth in the market (~5% market share), then conversely, it means that three competitors have better products. If the aim is to grow faster than the market in the future, it is unlikely to happen, at least initially. Customers are unlikely to perceive the products as better just because the owner’s name changes to Revenio.
In the future (= in a few years), this may change if the new company invests in R&D and tries to reach the winner’s circle.
Question: What is management’s vision for R&D investments in the coming years, and specifically what do they plan to do with the Visionix OCT product family? This question is partly related to the allocation of cash flow in the coming years and where management believes they will find the best return on capital.